KR101059379B1 - 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 - Google Patents

아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR101059379B1
KR101059379B1 KR1020057020862A KR20057020862A KR101059379B1 KR 101059379 B1 KR101059379 B1 KR 101059379B1 KR 1020057020862 A KR1020057020862 A KR 1020057020862A KR 20057020862 A KR20057020862 A KR 20057020862A KR 101059379 B1 KR101059379 B1 KR 101059379B1
Authority
KR
South Korea
Prior art keywords
formula
compound
group
formulas
suitable conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057020862A
Other languages
English (en)
Korean (ko)
Other versions
KR20060057531A (ko
Inventor
그레고리 엔. 비취
루이스 슈 륭 최
그레이스 정
위종 류
버트랜드 플러비어
리처드 월
제프 주
알렉산더 졸로토이
안쏘니 지. 엠. 바렛
마이클 제이.에이. 워커
산드로 엘. 용
타오 성
더웅 타 훙 처우
Original Assignee
카디오메 파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카디오메 파마 코포레이션 filed Critical 카디오메 파마 코포레이션
Publication of KR20060057531A publication Critical patent/KR20060057531A/ko
Application granted granted Critical
Publication of KR101059379B1 publication Critical patent/KR101059379B1/ko
Assigned to 코레비오 캐나다 코포레이션 reassignment 코레비오 캐나다 코포레이션 권리의 전부이전등록 Assignors: 코레비오 파마 코포레이션
Assigned to 코레비오 인터내셔널 에스에이알엘 reassignment 코레비오 인터내셔널 에스에이알엘 권리의 전부이전등록 Assignors: 코레비오 캐나다 코포레이션
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020057020862A 2003-05-02 2003-10-31 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Expired - Lifetime KR101059379B1 (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US46715903P 2003-05-02 2003-05-02
US60/467,159 2003-05-02
US47608303P 2003-06-04 2003-06-04
US60/476,083 2003-06-04
US47644703P 2003-06-05 2003-06-05
US47588403P 2003-06-05 2003-06-05
US47591203P 2003-06-05 2003-06-05
US60/475,884 2003-06-05
US60/475,912 2003-06-05
US60/476,447 2003-06-05
US48965903P 2003-07-23 2003-07-23
US60/489,659 2003-07-23
US49339203P 2003-08-07 2003-08-07
US60/493,392 2003-08-07
PCT/US2003/034655 WO2004099137A1 (en) 2003-05-02 2003-10-31 Aminocyclohexyl ether compounds and uses thereof

Publications (2)

Publication Number Publication Date
KR20060057531A KR20060057531A (ko) 2006-05-26
KR101059379B1 true KR101059379B1 (ko) 2011-08-26

Family

ID=33437310

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057020862A Expired - Lifetime KR101059379B1 (ko) 2003-05-02 2003-10-31 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (21)

Country Link
US (3) US20070099983A1 (cg-RX-API-DMAC7.html)
EP (3) EP1666459B1 (cg-RX-API-DMAC7.html)
JP (2) JP4919661B2 (cg-RX-API-DMAC7.html)
KR (1) KR101059379B1 (cg-RX-API-DMAC7.html)
AT (2) ATE529401T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003287378B2 (cg-RX-API-DMAC7.html)
BR (2) BR122018009866B8 (cg-RX-API-DMAC7.html)
CA (1) CA2524323C (cg-RX-API-DMAC7.html)
CY (1) CY1105137T1 (cg-RX-API-DMAC7.html)
DE (1) DE60305200T2 (cg-RX-API-DMAC7.html)
DK (1) DK1560812T3 (cg-RX-API-DMAC7.html)
ES (2) ES2375820T3 (cg-RX-API-DMAC7.html)
IL (2) IL171653A (cg-RX-API-DMAC7.html)
NO (1) NO334094B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ543921A (cg-RX-API-DMAC7.html)
PL (1) PL227937B1 (cg-RX-API-DMAC7.html)
PT (1) PT1560812E (cg-RX-API-DMAC7.html)
RU (1) RU2478617C2 (cg-RX-API-DMAC7.html)
SG (2) SG2010079697A (cg-RX-API-DMAC7.html)
SI (1) SI1560812T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004099137A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217918C (zh) 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
DE60305200T2 (de) * 2003-05-02 2007-05-10 Cardiome Pharma Corp. Aminocyclohexylether-verbindungen und deren verwendung
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
CA2561733A1 (en) * 2004-04-01 2005-10-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
JP5583325B2 (ja) * 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
US8692002B2 (en) 2004-11-18 2014-04-08 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
US20090005576A1 (en) * 2005-01-12 2009-01-01 Astellas Pharma Inc. Production Method of Optically Active Cyclohexane Ether Compounds
JP5159616B2 (ja) * 2005-06-15 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の調製のための合成プロセス
DE602006018182D1 (de) 2005-08-23 2010-12-23 Kaneka Corp Verfahren zur herstellung von aralkyloxypyrrolidinderivaten
JP2007131597A (ja) * 2005-11-11 2007-05-31 Toray Fine Chemicals Co Ltd ベンジルオキシピロリジン誘導体の製造方法
JP5004067B2 (ja) * 2005-10-31 2012-08-22 東レ・ファインケミカル株式会社 ベンジルオキシ含窒素環状化合物の製造法
JP5004073B2 (ja) * 2006-06-13 2012-08-22 東レ・ファインケミカル株式会社 光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体及びその製造法
EP1950198B1 (en) * 2005-10-31 2014-08-06 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
US20080312309A1 (en) * 2007-05-04 2008-12-18 Cardiome Pharma Corp. Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
WO2012024100A2 (en) 2010-08-16 2012-02-23 Merck Sharp & Dohme Corp. Process for preparing aminocyclohexyl ether compounds
US8932836B2 (en) 2010-08-16 2015-01-13 Codexis, Inc. Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
EP3174935B1 (de) * 2014-08-01 2023-06-21 Covestro Intellectual Property GmbH & Co. KG Copolycarbonat-zusammensetzungen mit cyclischen und linearen oligomeren und verbesserten optischen eigenschaften

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2954380A (en) * 1958-11-26 1960-09-27 Us Vitamin Pharm Corp Piperazinocyclohexyl esters
US3218328A (en) * 1963-02-18 1965-11-16 U S Vitamin & Pharmacentical C Heterocyclic amino phenoxyacetic acids, acid addition salts and quaternary ammonium salts thereof
DE2259260A1 (de) 1972-12-04 1974-06-06 Merck Patent Gmbh Neue amine
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4179501A (en) * 1976-11-12 1979-12-18 The Upjohn Company Analgesic N-(2-aminocycloaliphatic)azidobenzamides
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4598087A (en) * 1983-12-06 1986-07-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
AU580777B2 (en) * 1984-05-18 1989-02-02 Glaxo Group Limited Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
EP0248824B1 (en) 1985-10-25 1990-01-17 The Upjohn Company Use of cis-n-(2 aminocycloaliphatic) benzene acetamide and benzamide for the manufacture of anticonvulsants
US5059620A (en) * 1985-12-27 1991-10-22 The Du Pont Merck Pharmaceutical Company Aryl substituted aminomethyl benzene derivatives
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) * 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US4906655A (en) 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
JPH02270864A (ja) 1989-04-12 1990-11-05 Asahi Glass Co Ltd フルオロカルバサイクリックヌクレオシドおよびその製造法
US5428031A (en) 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2058502A1 (en) 1991-12-27 1993-06-28 David C. Horwell 2-amino-mono-methoxycyclohexyl amides useful as analgesics
EP0552386A1 (en) 1992-01-13 1993-07-28 Warner-Lambert Company 2-Amino-3 or 6-methoxycyclohexyl amide derivatives
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
ES2104142T3 (es) 1992-03-26 1997-10-01 Univ British Columbia Aminociclohexilamidas para utilizacion antirritmica y anestesica.
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
US5451596A (en) 1992-12-29 1995-09-19 Rhone Poulenc Rorer Pharmaceuticals Inc. Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5492825A (en) * 1993-08-06 1996-02-20 The Regents Of The University Of California Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
GB9406043D0 (en) * 1994-03-26 1994-05-18 Smithkline Beecham Plc Compounds
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
EP0804434A1 (en) * 1994-08-02 1997-11-05 MERCK SHARP & DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
US5556990A (en) 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
JP3789938B2 (ja) 1995-02-03 2006-06-28 ビーエーエスエフ アクチェンゲゼルシャフト 酵素触媒作用アシル化による1級及び2級のヘテロ原子置換アミンのラセミ体分割
BR9707081A (pt) 1996-01-25 1999-05-25 Schering Ag Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
CZ425598A3 (cs) 1996-06-27 1999-08-11 Smithkline Beecham Corporation Antagonista IL-8 receptoru
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
WO1999016431A1 (en) 1997-09-26 1999-04-08 Nortran Pharmaceuticals Inc. Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia
JP3773644B2 (ja) * 1998-01-06 2006-05-10 芝府エンジニアリング株式会社 接点材料
US6013830A (en) 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
CN1217918C (zh) * 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
US6624761B2 (en) * 1998-12-11 2003-09-23 Realtime Data, Llc Content independent data compression method and system
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
WO2000047547A2 (en) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
AU2899400A (en) 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
CA2268590A1 (en) * 1999-04-12 2000-10-12 Nortran Pharmaceuticals Inc. Ion channel modulating compounds and uses thereof
US6150357A (en) 1999-05-10 2000-11-21 Merck & Co., Inc. Potassium channel agonists
JP4219590B2 (ja) * 2000-04-20 2009-02-04 エフ.ホフマン−ラ ロシュ アーゲー ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
WO2003105756A2 (en) * 2002-06-14 2003-12-24 Johnson Matthey Pharmaceutical Materials, Inc. Stereoselective synthesis of 1,2-disubstituted cycloalkyls
US20060167226A1 (en) 2002-07-12 2006-07-27 Cardiome Pharma Corp. Mutations of voltage-gated ion channnels that allow them to express a voltage-independent phenotype and an improved method to use the same
CA2524034A1 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
DE60305200T2 (de) 2003-05-02 2007-05-10 Cardiome Pharma Corp. Aminocyclohexylether-verbindungen und deren verwendung
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2005016242A2 (en) * 2003-06-04 2005-02-24 Cardiome Pharma Corp. Synthetic process for trans-aminocyclohexyl ether compounds
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20070197632A1 (en) 2003-10-31 2007-08-23 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof

Also Published As

Publication number Publication date
SG2010079697A (en) 2016-09-29
BR122018009866B8 (pt) 2021-07-27
US7767830B2 (en) 2010-08-03
ATE325789T1 (de) 2006-06-15
AU2003287378B2 (en) 2010-12-16
BR122018009866B1 (pt) 2018-12-18
IL171653A (en) 2013-06-27
US20110004006A1 (en) 2011-01-06
EP1666459A2 (en) 2006-06-07
IL216579A (en) 2015-02-26
ATE529401T1 (de) 2011-11-15
BRPI0318278B1 (pt) 2018-11-06
HK1091814A1 (zh) 2007-01-26
JP2007077162A (ja) 2007-03-29
US20070254945A1 (en) 2007-11-01
BRPI0318278B8 (pt) 2024-01-09
NO20055130D0 (no) 2005-11-02
EP1560812B1 (en) 2006-05-10
PL378918A1 (pl) 2006-06-12
ES2264776T3 (es) 2007-01-16
US20070099983A1 (en) 2007-05-03
NO334094B1 (no) 2013-12-09
NO20055130L (no) 2005-12-01
CY1105137T1 (el) 2010-03-03
NZ543921A (en) 2008-11-28
DE60305200D1 (de) 2006-06-14
WO2004099137A1 (en) 2004-11-18
PT1560812E (pt) 2006-09-29
US8163938B2 (en) 2012-04-24
AU2003287378A1 (en) 2004-11-26
EP2298735A1 (en) 2011-03-23
SG167670A1 (en) 2011-01-28
JP2006525227A (ja) 2006-11-09
DK1560812T3 (da) 2006-09-04
SI1560812T1 (sl) 2006-10-31
EP1560812A1 (en) 2005-08-10
KR20060057531A (ko) 2006-05-26
EP1666459A3 (en) 2006-09-20
IL216579A0 (en) 2012-01-31
RU2478617C2 (ru) 2013-04-10
CA2524323C (en) 2012-05-15
PL227937B1 (pl) 2018-01-31
EP1666459B1 (en) 2011-10-19
DE60305200T2 (de) 2007-05-10
BR0318278A (pt) 2006-05-23
RU2008104198A (ru) 2009-08-10
ES2375820T3 (es) 2012-03-06
AU2011201015A1 (en) 2011-03-31
JP4919661B2 (ja) 2012-04-18
AU2011201015B2 (en) 2012-02-02
CA2524323A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
RU2478617C2 (ru) Способы получения соединений простого аминоциклогексилового эфира и промежуточные соединения и способы их получения
US7875611B2 (en) Ion channel modulating compounds and uses thereof
JP2006525227A5 (cg-RX-API-DMAC7.html)
US20160008322A1 (en) Ion channel modulating compounds and uses thereof
US7345087B2 (en) Aminocyclohexyl ether compounds and uses thereof
CA2268590A1 (en) Ion channel modulating compounds and uses thereof
RU2330017C2 (ru) Соединения простого аминоциклогексилового эфира и способы их применения
ZA200509759B (en) Aminocyclohexyl ether compounds and uses thereof
HK1091814B (en) Aminocyclohexyl ether compounds and uses thereof
MXPA05011809A (en) Aminocyclohexyl ether compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081031

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101022

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110620

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110819

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110822

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140806

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140806

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150805

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150805

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160808

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160808

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170809

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170809

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180808

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180808

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190807

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190807

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200812

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210810

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20240430

Termination category: Expiration of duration